Gaba Labs Secures Nearly £500k to Advance Alcohol Alternatives

Gaba Labs Ltd, a Hemel Hempstead-based innovator in functional ingredients and beverages, has successfully raised £499.7k in its latest funding round. The company specialises in developing alcohol alternatives designed to promote relaxation and social connection without the intoxicating effects of alcohol.

Incorporated on May 18, 2016, Gaba Labs addresses a growing market need for sophisticated non-alcoholic options for adult social drinkers. The company's pioneering team of scientists focuses on creating new functional ingredients that mimic the desired effects of alcohol. Their product portfolio includes Sentia, a botanical spirit, and Alcarelle, a biomimetic ingredient. Alcarelle is currently being prepared for the FDA GRAS (Generally Recognized As Safe) regulatory pathway in the US. Upon successful validation, Gaba Labs intends to license Alcarelle to the drinks industry, paving the way for a new generation of beverages.

According to the latest available accounts, Gaba Labs reported two employees. However, its LinkedIn profile indicates a team of nine, suggesting recent growth in its biotechnology research and development efforts. The company lists its specialties as GABA Research, Alcohol alternatives, and GABAergic ingredients, underscoring its scientific approach to beverage innovation.

This recent funding round, with an estimated size of £499.7k, was filed on April 27, 2026, following an allotment date of March 3, 2026. While a specific valuation for this round has not been disclosed, this capital injection marks a significant step for the company.

Gaba Labs has demonstrated a consistent pattern of securing capital through multiple smaller rounds over the past two years. Prior funding activities include: - £100.1k on December 8, 2025 - £100.1k on October 29, 2025 - £50k on October 28, 2025 - £50k on February 7, 2025 - £100k on December 14, 2024 - £49.3k on August 15, 2024 - £100k on July 23, 2024 - £50k on May 13, 2024 - £100.1k on March 20, 2024 - £57.7k on March 19, 2024

These previous rounds, totaling approximately £757.3k prior to the latest raise, highlight the company's strategy of incremental funding to support its research and development, particularly in advancing Alcarelle through regulatory processes. The latest £499.7k round represents the largest single raise documented for the company to date, indicating increasing investor confidence and momentum.

The UK market for innovative food and beverage companies, particularly those in the functional and alcohol-alternative space, continues to evolve. Consumers are increasingly seeking healthier lifestyle choices, which includes a growing demand for sophisticated non-alcoholic options. Gaba Labs is positioned to capitalise on this trend by offering scientifically-backed ingredients that deliver desired social effects without the drawbacks of alcohol. The company's focus on the regulatory pathway for Alcarelle underscores its ambition to become a key ingredient supplier to the global drinks industry, rather than solely a direct-to-consumer brand.

This latest funding will be instrumental in accelerating Gaba Labs' mission to bring its innovative ingredients to market, particularly as it navigates the complex regulatory environment for novel food components like Alcarelle. The company's commitment to scientific rigor and addressing a significant societal shift towards mindful drinking positions it as a notable player within the UK's burgeoning biotech and food tech sectors.